Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

lar novel nuclear Therapeutics 47 export inhibitors (NEIs) in multiple xenograft models 4/18 8:00- 5609 Nuclear Export Experimental 29 14 12:00 Inhibitors and Molecular (NEIs) as novel Therapeutics 47 cancer therapeutics

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan
'"/>





Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
(Date:12/24/2014)... 23, 2014 In response to urgent requests from the ... Sierra Leone , Direct Relief delivered two 10-bed ... the treatment of local health workers who contract Ebola while ... Ebola care center was constructed for foreign health care workers ... available for local Sierra Leonean health workers. With ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Aug. 3 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time ( 5:00 ... Interested parties may access ... , , ...
... , CLEVELAND , Aug. 3 Researchers ... Washington University School of Medicine in St. Louis, ... use of advanced treatments for cancer patients, will soon become ... system from ViewRay™, Inc. The ViewRay system is designed to ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 2Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... of $39.2 MillionCARLSBAD, Calif., April 30 Genoptix, Inc. ... provider, today reported revenues of $39.2 million for the ... benefit from changes in accounting estimates relating to prior ... over revenues of $22.3 million for the comparable period ...
... risks, agency says, , , THURSDAY, April 30 (HealthDay News) ... injections such as Botox to treat muscle spasms have ... products will now be required to carry boxed warnings, ... Food and Drug Administration announced Thursday. , Most cases ...
... HealthSouth Corporation (NYSE: HLS ) today announced ... Stock Conference on May 12-14, 2009, at the Four Seasons ... and Executive Vice President and Chief Financial Officer John Workman ... ET (7:55 a.m. CT). The presentation will be webcast live ...
... The Missouri House today amended HB21 to allocate at ... grants for maternity homes and pregnancy resource centers in the ... Missouri Senate. , , Americans United for Life ... centers are essential to helping pregnant women in need. ...
... Prospero Group (PRPG) invested into the Private ... split. Prospero Group a leading company in the field ... the new ACTRx Malaria and Dengue fever treatment. Fincor ... Prospero Group enlarges its technology portfolio with ...
... can have significant physical and psychological repercussions that impact ... it can affect their ability to remain employed. Compared ... disabilities, arthritis appears to have a more profound effect ... found that about half of those with severe forms ...
Cached Medicine News:Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 2Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 3Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 4Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 5Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 6Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 7Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 8Health News:Genoptix Reports Strong Growth for the First Quarter of 2009 9Health News:FDA Mandates New Warnings for Botox 2Health News:FDA Mandates New Warnings for Botox 3Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Women with arthritis more likely than men to stop working 2Health News:Women with arthritis more likely than men to stop working 3
... Prostate specific antigen (PSA) is a serine ... within the epithelial cells of the acini and ... serum is 0.1-2.6 ng/mL. Reports have suggested that ... is the must useful tumor markers in diagnosis ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
A complete workstation for haemostasis , A compact and convenient analyser , A comprehensive system , An exellent reliability: the STAGO patented detection mode...
... Lancets are designed with Shallow Point Comfort ... gauge needle with its shallow-angled edges act ... penetration without tearing the skin. The unique ... to grip, even for patients with arthritis ...
Medicine Products: